Arcus Biosciences (RCUS) president awarded RSUs and 126,000-share option

Rhea-AI Filing Summary

Arcus Biosciences, Inc. reported new equity awards for President Juan C. Jaen. On January 23, 2026, he received 31,000 shares of common stock as restricted stock units at a grant price of $0. These RSUs vest in four equal annual installments beginning December 15, 2026, contingent on his continued service, bringing his directly held common stock to 377,012 shares, including unvested RSUs. He also received a stock option for 126,000 shares of common stock with an exercise price of $22.13 per share. This option becomes exercisable in 48 equal monthly installments after January 1, 2026, and all 126,000 option shares are reported as directly owned. In addition, 922,240 shares of common stock are reported as indirectly owned through a trust.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jaen Juan C.

(Last) (First) (Middle)

C/O ARCUS BIOSCIENCES, INC.

3928 POINT EDEN WAY

(Street)

HAYWARD CA 94545

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Arcus Biosciences, Inc. [ RCUS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President

3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/23/2026		A		31,000(1)	A	$0	377,012(2)	D
Common Stock								922,240	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$22.13	01/23/2026		A		126,000		(3)	01/22/2036	Common Stock	126,000	$0	126,000	D

Explanation of Responses:

1. Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company.

2. Includes the unvested portion of the Reporting Person's RSU grants.

3. The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company.

Remarks:

	/s/ Carolyn Tang, Attorney-in-Fact	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Arcus Biosciences (RCUS) report for its president?

Arcus Biosciences reported that President Juan C. Jaen received equity awards on January 23, 2026, including restricted stock units and a stock option, all reported on a Form 4.

How many Arcus Biosciences (RCUS) shares did Juan C. Jaen receive as restricted stock units?

Juan C. Jaen received 31,000 shares of common stock as restricted stock units at a grant price of $0, vesting over four years starting December 15, 2026.

What are the terms of the stock option granted to the Arcus Biosciences (RCUS) president?

He was granted a stock option for 126,000 shares of Arcus common stock with an exercise price of $22.13 per share. The option becomes exercisable in 48 equal monthly installments after January 1, 2026 and expires on January 22, 2036.

How many Arcus Biosciences (RCUS) shares does Juan C. Jaen own after the reported transactions?

Following the reported grants, he directly beneficially owns 377,012 shares of common stock, including unvested RSUs, and indirectly beneficially owns 922,240 shares through a trust.

Are the equity awards to the Arcus Biosciences (RCUS) president tied to continued service?

Yes. The 31,000-share RSU grant vests in four equal annual installments beginning December 15, 2026, and the 126,000-share option vests in 48 monthly installments after January 1, 2026, each subject to his continued service to the company.

Did the Arcus Biosciences (RCUS) president pay cash for the new equity grants?

The 31,000 RSUs and the 126,000-share option grant were reported with a grant price of $0 for the awards themselves, while the option has an exercise price of $22.13 per underlying share.